Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Total Non-Current Liabilities (2016 - 2022)

vTv Therapeutics (VTVT) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $13.1 million as the latest value for Q1 2022.

  • Quarterly Total Non-Current Liabilities rose 27.19% to $13.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Mar 2022, up 27.19% year-over-year, with the annual reading at $9.0 million for FY2021, 17.87% down from the prior year.
  • Total Non-Current Liabilities hit $13.1 million in Q1 2022 for vTv Therapeutics, up from $9.0 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $43.2 million in Q2 2018 to a low of $8.3 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $19.9 million across 5 years, with a median of $16.8 million in 2020.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 44.95% in 2018 and later tumbled 49.82% in 2019.
  • Year by year, Total Non-Current Liabilities stood at $28.7 million in 2018, then tumbled by 37.75% to $17.8 million in 2019, then tumbled by 38.66% to $10.9 million in 2020, then decreased by 17.87% to $9.0 million in 2021, then skyrocketed by 46.17% to $13.1 million in 2022.
  • Business Quant data shows Total Non-Current Liabilities for VTVT at $13.1 million in Q1 2022, $9.0 million in Q4 2021, and $8.3 million in Q3 2021.